Table 3.
Parameter | Period |
HS219 |
Placebo |
Mean difference a | 95% CI | U test | ||
---|---|---|---|---|---|---|---|---|
n | Mean ± SD | n | Mean ± SD | |||||
Serum phosphorus (mg/dl) |
Baseline |
35 |
6.7 ± 1.0 |
28 |
6.5 ± 1.3 |
0.2 |
-0.5 ~ 0.8 |
P = 0.677 |
Week 3 |
32 |
6.4 ± 1.4 |
28 |
6.3 ± 1.3 |
0.1 |
-0.6 ~ 0.8 |
P = 0.900 |
|
Salivary phosphorus (mg/dl) |
Baseline |
35 |
24.0 ± 10.4 |
28 |
23.7 ± 8.9 |
0.2 |
-4.6 ~ 5.1 |
P = 0.964 |
Week 3 |
32 |
22.3 ± 8.0 |
28 |
21.5 ± 9.0 |
0.8 |
-3.6 ~ 5.2 |
P = 0.656 |
|
Serum Ca (mg/dl) |
Baseline |
35 |
9.3 ± 0.7 |
28 |
9.2 ± 0.6 |
0.2 |
-0.1 ~ 0.5 |
P = 0.299 |
Week 3 |
33 |
9.4 ± 0.7 |
28 |
9.1 ± 0.6 |
0.2 |
-0.1 ~ 0.6 |
P = 0.149 |
|
Serum Ca x P (mg2/dl2) |
Baseline |
35 |
62.0 ± 10.3 |
28 |
59.3 ± 11.1 |
2.7 |
-2.8 ~ 8.2 |
P = 0.490 |
Week 3 |
33 |
59.9 ± 13.9 |
28 |
57.2 ± 11.3 |
2.7 |
-3.8 ~ 9.1 |
P = 0.520 |
|
iPTH (pg/ml) |
Baseline |
35 |
233 ± 148 |
28 |
233 ± 156 |
1 |
-77 ~ 78 |
P = 0.760 |
Week 3 |
33 |
207 ± 141 |
28 |
251 ± 184 |
-45 |
-130 ~ 41 |
P = 0.511 |
|
whole PTH (pg/ml) |
Baseline |
35 |
133 ± 89 |
28 |
137 ± 97 |
-4 |
-51 ~ 44 |
P = 0.899 |
Week 3 |
33 |
118 ± 92 |
28 |
140 ± 102 |
-22 |
-72 ~ 28 |
P = 0.511 |
|
iFGF23 (log10 pg/ml) | Baseline |
35 |
4.1 ± 0.5 |
28 |
4.0 ± 0.6 |
0.1 |
-0.2 ~ 0.3 |
P = 0.736 |
Week 3 | 33 | 4.0 ± 0.5 | 28 | 4.0 ± 0.5 | 0.0 | -0.3 ~ 0.3 | P = 0.960 |
aMean difference between HS219 and placebo of group at baseline or week 3.